Brivudine 125mg tablets

BACKGROUND AND OBJECTIVE: Brivudine has been used in herpes zoster (HZ) treatment for years, but the safety and efficacy of brivudine are inconclusive. Here we perform a meta-analysis to assess the efficacy, safety, incidence of postherpetic neuralgia of brivudine. METHODS: Data of randomized controlled Trials (RCTS) were obtained from the databases of both English (PubMed, Embase, and Cochrane Library) and Chinese (China National Knowledge Infrastructure, China Science Journal Database, and WanFang Database) literatures from inception to 12 September 2022. Meta-analyses of efficacy and safety of Brivudine for the treatment of herpes zoster for RCTS were conducted. RESULTS: > .05). CONCLUSIONS: Brivudine is effective for HZ. However, the evidence on the safety of brivudine is insufficient.

Abstract licence: CC BY-NC 4.0

Herpes zoster is a viral skin infection caused by the reactivation of the varicella-zoster virus, which remains latent in the dorsal root ganglia of the spinal cord and the cranial sensory ganglia. One of the most widely used classes of antiviral agents in the treatment of herpes zoster is nucleoside analogs. This study aims to review the use of nucleoside analogs in the management of herpes zoster. The method employed was a literature review of relevant research articles. The findings indicate that nucleoside analogs commonly used in herpes zoster therapy include acyclovir, valacyclovir, famciclovir, and brivudine. These agents are administered in various doses, routes, and therapeutic purposes, such as alleviating acute symptoms, accelerating skin lesion healing, preventing postherpetic neuralgia, and serving as prophylactic therapy in special conditions such as cancer or organ transplantation. Overall, the use of nucleoside analogs has proven effective in inhibiting varicella-zoster virus replication, reducing symptom intensity, and minimizing the risk of complications.

Abstract licence: CC BY

Brivudine is a thymidine analogue antiviral agent used in the treatment of herpes zoster; however, human data regarding its use during pregnancy are lacking. This report aims to describe pregnancy outcomes following oral brivudine exposure and to provide the first human clinical data on brivudine use during pregnancy. Two pregnant women exposed to oral brivudine during the first and second trimesters were referred for teratological risk assessment and followed with perinatal monitoring and postnatal clinical follow-up. Both pregnancies were continued with perinatological follow-up and resulted in the delivery of healthy infants without major congenital malformations. Postnatal follow-up identified mild allergic manifestations in one child and an isolated mild delay in the personal-social developmental domain in the other. These cases provide preliminary clinical data on brivudine exposure during pregnancy and contribute to the limited human data available.

Abstract licence: CC BY 4.0

A 64-year-old man presented with painful rash on the trunk and extremities for more than half a month. Nephrotic syndrome had been diagnosed 2 years ago and had been regularly treated with glucocorticoids and immunosuppressants. He developed herpes zoster 1 year ago. Laboratory investigation demonstrated varicella-zoster virus DNA (VZV-DNA), varicella-zoster virus IgM (VZV-IgM), and varicella-zoster virus antibody IgG (VZV-IgG) were all positive. After the clinical diagnosis of relapsed disseminated cutaneous herpes zoster had been confirmed, systemic therapy with brivudine 125 mg everyday was started.

Abstract licence: CC BY-NC 4.0